Evaluation of serum level of substance P and tissue distribution of NK-1 receptor in endometrial cancer

Severini C, Improta G, Falconieri-Erspamer G, Salvadori S, Erspamer V (2002) The tachykinin peptide family. Pharmacol Rev 54(2):285–322 Steinhoff MS, von Mentzer B, Geppetti P, Pothoulakis C, Bunnett NW (2014) Tachykinins and their receptors: contributions to physiological control and the mechanisms of disease. Physiol Rev 94(1):265–301. https://doi.org/10.1152/physrev.00031.2013 Gaddum J (1931) An unidentified depressor substance in certain tissue extracts. J Physiol 72(1):74–87 Garcia-Recio S, Gascón P (2015) Biological and pharmacological aspects of the NK1-Receptor. BioMed Res Int. https://doi.org/10.1155/2015/495704 Datar P, Srivastava S, Coutinho E, Govil G (2004) Substance P: structure, function, and therapeutics. Curr Top Med Chem 4(1):75–103 Bossaller C, Reither K, Hehlert-Friedrich C, Auch-Schwelk W, Graf K, Grafe M, Fleck E (1992) In vivo measurement of endothelium-dependent vasodilation with substance P in man. Herz 17(5):284–290 Eklund B, Jogestrand T, Pernow B (1977) Effect of substance P on resistance and capacitance vessels in the human forearm. In: von Euler US, Pernow B (eds) Substance P. Raven Press, New York Shimizu Y, Matsuyama H, Shiina T, Takewaki T, Furness J (2008) Tachykinins and their functions in the gastrointestinal tract. Cell Mol Life Sci 65(2):295–311 Saito R, Takano Y, Kamiya HO (2003) Roles of substance P and NK(1) receptor in the brainstem in the development of emesis. J Pharmacol Sci 91(2):87–94 Fields HL, Levine JD (1984) Pain–mechanics and management. West J Med 141(3):347–357 Klassert TE, Patel SA, Rameshwar P (2010) Tachykinins and neurokinin receptors in bone marrow functions: neural-hematopoietic link. J Recept Ligand Channel Res 3:51–61 Nabzdyk LP, Kuchibhotla S, Guthrie P, Chun M, Auster ME, Nabzdyk C, Deso S, Andersen N, Gnardellis C, LoGerfo FW (2013) Expression of neuropeptides and cytokines in a rabbit model of diabetic neuroischemic wound healing. J Vasc Surg 58(3):766–775 (e712) Rosso M, Robles-Frías MJ, Coveñas R, Salinas-Martín MV, Muñoz M (2008) The NK-1 receptor is expressed in human primary gastric and colon adenocarcinomas and is involved in the antitumor action of L-733,060 and the mitogenic action of substance P on human gastrointestinal cancer cell lines. Tumor Biol 29(4):245–254 Friess H, Zhu Z, Liard V, Shi X, Shrikhande SV, Wang L, Lieb K, Korc M, Palma C, Zimmermann A (2003) Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab Investig 83(5):731–742 Singh D, Joshi DD, Hameed M, Qian J, Gascón P, Maloof PB, Mosenthal A, Rameshwar P (2000) Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells: implications for bone marrow metastasis. Proc Natl Acad Sci USA 97(1):388–393 Munoz M, Gonzalez-Ortega A, Rosso M, Robles-Frias MJ, Carranza A, Salinas-Martin MV, Covenas R (2012) The substance P/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists. Peptides 38(2):318–325. https://doi.org/10.1016/j.peptides.2012.09.024 Muñoz M, Rosso M, Robles-Frias MJ, Salinas-Martín MV, Rosso R, González-Ortega A, Coveñas R (2010) The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines. Lab Investig 90(8):1259–1269 Harkins J, Roper M, Ham RG, Stewart JM (1978) Biosynthesis of substance P in cultured mouse neuroblastoma and rat glioma cells. Brain Res 147(2):405–409 Ma J, Yuan S, Cheng J, Kang S, Zhao W, Zhang J (2016) Substance P promotes the progression of endometrial adenocarcinoma. Int J Gynecol Cancer: Off J Int Gynecol Cancer Soc 26(5):845–850. https://doi.org/10.1097/igc.0000000000000683 Akazawa T, Kwatra SG, Goldsmith LE, Richardson MD, Cox EA, Sampson JH, Kwatra MM (2009) A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor-mediated apoptosis in glioblastomas. J Neurochem 109(4):1079–1086 Bigioni M, Benzo A, Irrissuto C, Maggi CA, Goso C (2005) Role of NK-1 and NK-2 tachykinin receptor antagonism on the growth of human breast carcinoma cell line MDA-MB-231. Anti-Cancer Drugs 16(10):1083–1089 Entschladen F, Lang K, Drell TL, Joseph J, Zaenker KS (2002) Neurotransmitters are regulators for the migration of tumor cells and leukocytes. Cancer Immunol Immunother 51(9):467–482 Guha S, Eibl G, Kisfalvi K, Fan RS, Burdick M, Reber H, Hines OJ, Strieter R, Rozengurt E (2005) Broad-spectrum G protein-coupled receptor antagonist, [D-Arg1,D-Trp5,7,9,Leu11]SP: a dual inhibitor of growth and angiogenesis in pancreatic cancer. Cancer Res 65(7):2738–2745. https://doi.org/10.1158/0008-5472.can-04-3197 Munoz M, Gonzalez-Ortega A, Covenas R (2012) The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic leukemia cell lines. Investig New Drugs 30(2):529–540. https://doi.org/10.1007/s10637-010-9594-0 Munoz M, Rosso M, Perez A, Covenas R, Rosso R, Zamarriego C, Piruat JI (2005) The NK1 receptor is involved in the antitumoural action of L-733,060 and in the mitogenic action of substance P on neuroblastoma and glioma cell lines. Neuropeptides 39(4):427–432. https://doi.org/10.1016/j.npep.2005.03.004 Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F (2015) Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136(5):E359–E386. https://doi.org/10.1002/ijc.29210 Arab M, Noghabaei G, Kazemi SN (2014) Comparison of crude and age-specific incidence rates of breast, ovary, endometrium and cervix cancers in Iran, 2005. Asian Pac J Cancer Prevent: APJCP 15(6):2461–2464 Plataniotis G, Castiglione M, Group EGW (2010) Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 21(suppl 5):v41–v45 Faria SC, Sagebiel T, Balachandran A, Devine C, Lal C, Bhosale PR (2015) Imaging in endometrial carcinoma. Indian J Radiol Imaging 25(2):137–147. https://doi.org/10.4103/0971-3026.155857 Reddy BY, Greco SJ, Patel PS, Trzaska KA, Rameshwar P (2009) RE-1–silencing transcription factor shows tumor-suppressor functions and negatively regulates the oncogenic TAC1 in breast cancer cells. Proc Natl Acad Sci. https://doi.org/10.1073/pnas.0809130106 Rosso M, Munoz M, Berger M (2012) The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer. Sci World J. https://doi.org/10.1100/2012/381434 Simeonidis S, Castagliuolo I, Pan A, Liu J, Wang CC, Mykoniatis A, Pasha A, Valenick L, Sougioultzis S, Zhao D, Pothoulakis C (2003) Regulation of the NK-1 receptor gene expression in human macrophage cells via an NF-kappa B site on its promoter. Proc Natl Acad Sci USA 100(5):2957–2962. https://doi.org/10.1073/pnas.0530112100 Friess H, Zhu Z, Liard V, Shi X, Shrikhande SV, Wang L, Lieb K, Korc M, Palma C, Zimmermann A, Reubi JC, Buchler MW (2003) Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer. Lab Investig: A J Tech Methods Pathol 83(5):731–742